Brief: Inflarx Receives IND Acceptance To Proceed With A Phase IIB Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa
09/01/2018 13:56
Jan 9 (Reuters) - Inflarx Nv IFRX.O :
* INFLARX RECEIVES IND ACCEPTANCE TO PROCEED WITH A PHASE
IIB
TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA
* INFLARX NV - INTENDS TO INITIATE THE STUDY ON IFX-1 IN Q1
OF
2018
Source text for Eikon: ID:nBw7KTn7ka
Further company coverage: IFRX.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum